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I arrived in Boston during the summer of
1984, having been coaxed there by F. Ses-
sions Cole, III. The carrot was the shorten-
ing of residency to 2 years, and thus a return
to the lab all the quicker. Dr. Avery was
the chair of the department at that time,
and so supported my bid to enter the Spe-
cial Alternative Pathway. While that may
sound easy, I had unintentionally made it
more difficult by doing my internship as
my fourth year of medical school. To the
American Board of Pediatrics, on paper,
I had done only a year of residency, and
would not be board eligible if I left my
residency program. After much negotia-
tion, the Johns Hopkins University School
of Medicine recalled my diploma, and re-
issued it with a graduating date of 1982
rather than 1983. And thus I started my
fellowship after 2 years of official residency!
And did get back to the lab a year sooner
than otherwise.
The next issue to be solved was one of
housing. In order to access the Harvard
University housing office, I needed a note
from the chair. I believe this is the only per-
sonal note I have signed by Dr. Avery, but
it guaranteed me a place to live while get-
ting to work on my clinical and research
training.
More importantly, her own research
work was inspirational for me in my
research career. Namely, the ability to see
the importance in common observations
that others did not recognize. Her obser-
vation that babies who died of respiratory
distress syndrome (RDS) had no bubbles
in their airways, whereas babies who died
of other causes had these bubbles (1). This
seemingly simple observation lead to the
gastric aspirate shake test (2), the identi-
fication of lack of surfactant in RDS (3),
development of surfactant therapies (4),
development of pharmacotherapies (pre-
natal steroids) for the preventions of RDS
(5), etc. For my own work, I have tried to
make simple observations. My first sim-
ple observation was that the then recently
described non-oxidative metabolites of
ethanol, fatty acid ethyl esters (FAEE),
accumulate in adipose tissue, so they might
accumulate in meconium. Meconium is the
accumulated gastrointestinal contents dur-
ing gestation which is passed soon after
birth and is presumed to be metabolically
inert. Thus, meconium could be a dosime-
ter for prenatal ethanol exposure. I devel-
oped a simple method of extracting FAEE
from meconium (6), and then was able
to validate that they were associated with
maternal self-reported drinking during
pregnancy in several different populations
(7–9), and that they indicated children
at risk for poor neurodevelopmental out-
comes (10). I was even able to demonstrate
that they accumulate in sheep meconium
(11)! For these experiments, I received NIH
funding, several publications, and a patent!
The next simple observation was actu-
ally made by someone else – that patients
with fetal alcohol syndrome and patients
with a mutation in the gene for L1 cell
adhesion molecule (L1) had very similar
neuropathologies (12). This observation
led to the hypothesis that L1 is a target
for ethanol developmental neurotoxicity. I
was able to build on this observation that
the neurite outgrowth promoted by L1 was
exquisitely sensitive to ethanol, whereas
that promoted by laminin or N-cadherin
was not (13). This lead to my own simple
observation that, since L1 promotes neu-
rite outgrowth via trafficking through a
lipid raft compartment, and laminin and
N-cadherin do not, then ethanol may tar-
get the L1–lipid raft interaction (14). These
observations lead to the next series of sim-
ple questions, such as, if ethanol has an
effect on lipid raft trafficking, do other
solvents? (Answer – yes). If the lipid raft
is the target for ethanol, are there unique
and novel interventions for the impact
of ethanol on the developing central ner-
vous system? (Answer – yes). So, after sev-
eral grants and many publications, we are
poised to begin the next series of simple
observations that will hopefully improve
neurodevelopmental outcomes following
neurotoxicant exposure, including ethanol,
toluene, bilirubin, volatile anesthetics, and
chlorhexidine.
One more simple observation occurred
to me early in my career. The observation
was that we use adult blood to transfuse
into our very low birth weight (VLBW)
babies. Adults are known to be exposed
to lead, mercury, and other heavy metals,
some at occupational levels of exposure
that would be inappropriate and danger-
ous for children. Adults who work with lead
are monitored for their blood lead level
which can be as high as 45 mg/dL before
being removed from the position that is
causing the exposure. Yet, donated blood
is not screened for potentially high levels
of heavy metals. We have shown that the
blood lead concentration increases follow-
ing transfusions in VLBW, and that about
25% of donor blood has concerning lev-
els of lead (15, 16). We are now engaged
in research to determine if the cumulative
dose of lead or mercury is a risk factor
for poorer neurodevelopmental outcome
of our most vulnerable patients.
Thank you Dr. Avery for your gift of
simple observations!
www.frontiersin.org April 2014 | Volume 2 | Article 20 | 1
Bearer A gift of simple observations
REFERENCES
1. Avery ME. Surfactant deficiency in hyaline mem-
brane disease: the story of discovery. Am J Respir
Crit Care Med (2000) 161:1074–5. doi:10.1164/
ajrccm.161.4.16142
2. Farrell PM, Avery ME. Hyaline membrane disease.
Am Rev Respir Dis (1975) 111:657–88.
3. Avery ME, Mead J. Surface properties in relation
to atelectasis and hyaline membrane disease. AMA
J Dis Child (1959) 97:517–23.
4. Taeusch HW, Keough KM, Williams M, Slavin
R, Steele E, Lee AS, et al. Characterization
of bovine surfactant for infants with respira-
tory distress syndrome. Pediatrics (1986) 77:
572–81.
5. Rokos J, Vaeusorn O, Nachman R, Avery ME. Hya-
line membrane disease in twins. Pediatrics (1968)
42:204–5.
6. Bearer CF. Detection of Teratogen Exposure. US
patent no. 5,952,235 (1999).
7. Bearer CF, Jacobson JL, Jacobson SW, Barr D,
Croxford J, Molteno CD, et al. Validation of a
new biomarker of fetal exposure to alcohol.
J Pediatr (2003) 143:463–9. doi:10.1067/S0022-
3476(03)00442-6
8. Bearer CF, Lee S, Salvator AE, Minnes S, Swick
A, Yamashita T, et al. Ethyl linoleate in meco-
nium: a biomarker for prenatal ethanol exposure.
Alcohol Clin Exp Res (1999) 23:487–93. doi:10.
1097/00000374-199903000-00016
9. Bearer CF, Santiago LM, O’Riordan MA, Buck K,
Lee SC, Singer LT. Fatty acid ethyl esters: quanti-
tative biomarkers for maternal alcohol consump-
tion. J Pediatr (2005) 146:824–30. doi:10.1016/j.
jpeds.2005.01.048
10. Peterson J, Kirchner HL, Xue W, Minnes S, Singer
LT, Bearer CF. Fatty acid ethyl esters in meconium
are associated with poorer neurodevelopmental
outcomes to two years of age. J Pediatr (2008)
152:788–92. doi:10.1016/j.jpeds.2007.11.009
11. Littner Y, Cudd TA, O’Riordan MA, Cwik A, Bearer
CF. Elevated fatty acid ethyl esters in meconium
of sheep fetuses exposed in utero to ethanol – a
new animal model. Pediatr Res (2008) 63:164–8.
doi:10.1203/PDR.0b013e31815f651e
12. Charness ME, Safran RM, Perides G. Ethanol
inhibits neural cell-cell adhesion. J Biol Chem
(1994) 269:9304–9.
13. Bearer CF, Swick AR, O’Riordan MA, Cheng G.
Ethanol inhibits L1-mediated neurite outgrowth
in postnatal rat cerebellar granule cells. J Biol
Chem (1999) 274:13264–70. doi:10.1074/jbc.274.
19.13264
14. Tang N, Farah B, He M, Fox S, Malouf A, Littner
Y, et al. Ethanol causes the redistribution of L1
cell adhesion molecule in lipid rafts. J Neurochem
(2011) 119:859–67. doi:10.1111/j.1471-4159.2011.
07467.x
15. Bearer CF, Linsalata N, Yomtovian R, Walsh M,
Singer L. Blood transfusions: a hidden source of
lead exposure. Lancet (2003) 362:332. doi:10.1016/
S0140-6736(03)13989-X
16. Bearer CF, O’Riordan MA, Powers R. Lead expo-
sure from blood transfusion to premature infants.
J Pediatr (2000) 137:549–54. doi:10.1067/mpd.
2000.108273
Conflict of Interest Statement: The author declares
that the research was conducted in the absence of any
commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 18 February 2014; accepted: 08 March 2014;
published online: 24 April 2014.
Citation: Bearer CF (2014) How Mary Ellen Avery influ-
enced my career as an investigator. Front. Pediatr. 2:20.
doi: 10.3389/fped.2014.00020
This article was submitted to Neonatology, a section of
the journal Frontiers in Pediatrics.
Copyright © 2014 Bearer . This is an open-access article
distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with
these terms.
Frontiers in Pediatrics | Neonatology April 2014 | Volume 2 | Article 20 | 2
